Powered by HealthTechMovers.com
We added 5 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
AbbVie Inc., ABBV
Summary: AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
- Last Price: $180.69
- Price Change: $-0.07, -0.04%
- Yearly Gain: 12.64%
- Market Cap: $319.18B
- P/E Ratio: 66.43
Here are 3rd party ratings for ABBV:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 13% (218 out of 252)
What is the sentiment on the street regarding AbbVie Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in ABBV or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ABBV before you decide to make any investment.
Click here for chart >>
Merit Medical Systems, Inc., MMSI
Summary: Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices.
- Last Price: $72.29
- Price Change: $-2.84, -3.78%
- Yearly Gain: -2.35%
- Market Cap: $4.19B
- P/E Ratio: 44.62
Here are 3rd party ratings for MMSI:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 33% (84 out of 252)
What is the sentiment on the street regarding Merit Medical Systems, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in MMSI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MMSI before you decide to make any investment.
Click here for chart >>
ARS Pharmaceuticals, Inc., SPRY
Summary: ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.
- Last Price: $9.28
- Price Change: $-0.19, -2.01%
- Yearly Gain: 46.60%
- Market Cap: $895.53M
- P/E Ratio: -16.28
Here are 3rd party ratings for SPRY:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 36% (91 out of 252)
What is the sentiment on the street regarding ARS Pharmaceuticals, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Risk Not Mentioned
If you are interested in SPRY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on SPRY before you decide to make any investment.
Click here for chart >>
Perspective Therapeutics, Inc., CATX
Summary: Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash.
- Last Price: $1.46
- Price Change: $0.18, 14.06%
- Yearly Gain: 111.59%
- Market Cap: $856.90M
- P/E Ratio: -24.33
Here are 3rd party ratings for CATX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Sell, Top 36% (91 out of 252)
What is the sentiment on the street regarding Perspective Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in CATX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CATX before you decide to make any investment.
Click here for chart >>
Stoke Therapeutics, Inc., STOK
Summary: Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.
- Last Price: $13.08
- Price Change: $-0.41, -3.04%
- Yearly Gain: 59.12%
- Market Cap: $605.65M
- P/E Ratio: -5.5
Here are 3rd party ratings for STOK:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Stoke Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in STOK or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on STOK before you decide to make any investment.
Click here for chart >>
Thanks for reading!
